Economic evaluation on strategy for preventing mother-to-child transmission of hepatitis B in Zhejiang Province
10.3760/cma.j.issn.0253-9624.2019.07.010
- VernacularTitle: 浙江省预防乙型肝炎母婴传播策略的经济学评价
- Author:
Yanbing ZENG
1
;
Mingliang LUO
1
;
Hanqing HE
2
;
Xuan DENG
2
;
Shuyun XIE
2
;
Ya FANG
1
Author Information
1. School of Public Health, Xiamen University, Xiamen 361102, China
2. Expanded Program Immunization Department of Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou 310051, China
- Publication Type:Journal Article
- Keywords:
Hepatitis B;
Costs and cost analysis;
Mother-to-child transmission;
Benefit and effectiveness;
Markov Model
- From:
Chinese Journal of Preventive Medicine
2019;53(7):706-712
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To evaluate the cost-benefit and cost-effectiveness of current strategy for preventing mother-to-child transmission (PMTCT) of hepatitis B virus.
Methods:A decision tree model with the Markov process was developed and simulated over the lifetime of a birth cohort in Zhejiang Province in 2016. The current PMTCT strategy was compared with universal vaccination and non-vaccination. Costs were assessed from social perspective. Benefits were the savings from reduced costs associated with disease and effectiveness were measured by quality-adjusted of life-years (QALY) gained. The net present value (NPV), cost-benefit ratio (BCR) and incremental cost-effectiveness ratio (ICER) were calculated. Univariate and Probabilistic Sensitivity Analyses (PSA) were performed to assess parameter uncertainties. The parameters of costs and utilities value of hepatitis B-related disease came from the results of the field survey, which were obtained by face-to-face questionnaire survey combined with inpatient medical records, including eight county and municipal hospitals in Jinhua, Jiaxing and Taizhou. A total of 626 outpatients and 523 inpatient patients were investigated. The annual total costs of infection was calculated by combining the costs of outpatient and inpatient.
Results:The PMTCT strategy showed a net-gain as 38 323.78 CNY per person, with BCR as 21.10, which was higher than 36 357.80 CNY per person and 13.58 respectively of universal vaccination. Compared with universal vaccination, the PMTCT strategy would save 2 787.07 CNY per additional QALY gained for every person, indicating that PMTCT would be cost-saving. The most important parameters that could affect BCR and ICER were the vaccine coverage rate and costs of hepatitis B related diseases respectively. The PSA showed the PMTCT strategy was preferable as it would gain more QALY and save costs.
Conclusions:The PMTCT strategy appeared as highly cost-beneficial and highly cost-effective. High vaccination rate was a key factor of high economic value.
